MedTrace Logo

Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes

NCT03556098 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-05-10

No results posted yet for this study

Summary

In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia in patients with T1D.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

glucose-dependent insulinotropic peptide

Infusion of GIP

DRUG

Glucose-Dependent Insulin-Releasing Hormone[3-30]

Infusion of GIP antagonist GIP\[3-30\]

DRUG

Saline Solution

Infusion of Saline

Sponsors & Collaborators

  • Steno Diabetes Center Copenhagen

    lead OTHER

Principal Investigators

  • Filip K Knop, MD, PhD · Steno Diabetes Center Copenhagen, Clinical Metabolic Physiology

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-22
Primary Completion
2020-02-11
Completion
2020-02-11

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03556098 on ClinicalTrials.gov